Option chain shows key data for Citius Oncology's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Citius Oncology.

Citius Oncology (NASDAQ:CTOR) Stock, Option Chain

Citius Oncology

Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.

Cassava Sciences, Zoom, Kohl's, Rivian, Tesla: Why These 5 Stocks Are On Investors' Radars Today

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

CRDO

CTNT

CTOR

FRME

GELS

JANX

KITT

OMEX

OPTT

SGBX

SHIM

SOAR

Why Credo Technology Group Shares Are Trading Higher By 40%; Here Are 20 Stocks Moving Premarket

Citius Oncology Inc

Press Releases

Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA®) and LYMPHIR™ in Cancer Patients with Recurrent Solid Tumors

"Market Movers: CTOR, CTNT, PNPN.V, KITT, SHIM – More Stocks Inside to Watch"

Earnings

Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update

Citius Oncology, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update

Small Cap

Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives

Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025

Contracts

Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services

Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update

Citius Oncology, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update

CRDL

CTXR

GILD

PNPNF

PRSO

TSXV:PNPN

Agenus

Burning Rock Biotech Limited - American Depositary Shares

Burning Rock Biotech

Barinthus Biotherapeutics plc - American Depositary Shares

Barinthus Biotherapeutics

Celularity

Connect Biopharma Holdings Limited - American Depositary Shares

Connect Biopharma Hldgs

CytomX Therapeutics

Fortress Biotech

Werewolf Therapeutics, Inc. - Common Stock

Werewolf Therapeutics

iBio

ImmuCell

Immix Biopharma

Century Therapeutics, Inc. - Common Stock

Century Therapeutics

Kala Bio

Karyopharm Therapeutics Inc. - Common Stock

Karyopharm Therapeutics

Lantern Pharma

MAIA Biotechnology

Mersana Therapeutics, Inc. - Common Stock

Mersana Therapeutics

OKYO Pharma

Outlook Therapeutics, Inc. - Common Stock

Outlook Therapeutics

Radiopharm Theranostics Limited - American Depositary Shares

Radiopharm Theranostics

Repare Therapeutics

Serina Therapeutics

Spero Therapeutics

vTv Therapeutics Inc. - Class A Common Stock

vTv Therapeutics

X4 Pharmaceuticals

Maxim Group

EF Hutton

Comments

Citius Oncology

Citius Oncology (CTOR) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga